Philip J. Barter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philip J. Barter has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Kerry-Anne Rye
§Academic Medical Center, University of Amsterdam, The Netherlands
7 shared publications- Stephen J. Nicholls
Victorian Heart Institute, Monash University, Clayton, Australia
4 shared publications John J.P. Kastelein
From the Heart Research Institute and University of Sydney, Sydney, Australia (P.J.B., K.R.); Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada (J.T.); San Francisco General Hospital, San Francisco, CA (D.D.W.); Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands (S.M.B., J.J.P.K.); and Pfizer, Inc, New York, NY (A.B.).
3 shared publications- Kerry-Anne Rye
School of Medical Sciences, The University of New South Wales, Sydney, New South Wales, Australia
3 shared publications Scott M. Grundy
3 shared publicationsCharles L. Shear
§Academic Medical Center, University of Amsterdam, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 1 November 2014
- Published by Elsevier in IJC Metabolic & Endocrine
- Vol. 5, 61-66
Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER
- 1 November 2014
- Published by Elsevier in IJC Metabolic & Endocrine
- Vol. 5, 61-66
Open AccessAchievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER
- 1 January 2014
- Published by Elsevier in Clínica e Investigación en Arteriosclerosis
- Vol. 26 (1) , 33-37
Documento oficial de la Sociedad Internacional de Aterosclerosis: recomendaciones generales para el tratamiento de la dislipidemia. Resumen ejecutivo
- 1 January 2014
- Published by Elsevier in Clínica e Investigación en Arteriosclerosis
- Vol. 26 (1) , 33-37
Documento oficial de la Sociedad Internacional de Aterosclerosis: recomendaciones generales para el tratamiento de la dislipidemia. Resumen ejecutivo
- 1 May 2013
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 7 (3) , 284-285
Achievement of ATP III Combined LDL-C and Non-HDL-C Goals of <100 and <130 mg/dL or <70 and <100 mg/dL with 3 Different Statins: Results from VOYAGER
- 1 May 2013
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 7 (3) , 284-285
Achievement of ATP III Combined LDL-C and Non-HDL-C Goals of <100 and <130 mg/dL or <70 and <100 mg/dL with 3 Different Statins: Results from VOYAGER
- Open Access
- 1 November 2012
- Published by Elsevier in Journal of Lipid Research
- Vol. 53 (11) , 2436-2442
Relationship between atorvastatin dose and the harm caused by torcetrapib
- 1 November 2012
- Published by Elsevier in Journal of Lipid Research
- Vol. 53 (11) , 2436-2442
Open AccessRelationship between atorvastatin dose and the harm caused by torcetrapib
- 1 June 2012
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 56 (3) , 141-142
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
- 1 June 2012
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 56 (3) , 141-142
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
- 1 May 2012
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 6 (3) , 273
Alteration of Atherogenic Lipoproteins by Statin Therapy in Patients with Diabetes in a Large Pooled Clinical Trial Database†
- 1 May 2012
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 6 (3) , 273
Alteration of Atherogenic Lipoproteins by Statin Therapy in Patients with Diabetes in a Large Pooled Clinical Trial Database†
- 31 December 2011
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 32 (12) , 694-699
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?
- 31 December 2011
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 32 (12) , 694-699
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?
- 1 December 2011
- Published by Elsevier in Atherosclerosis
- Vol. 219 (2) , 392
Response to statin use and serum bilirubin levels
- 1 December 2011
- Published by Elsevier in Atherosclerosis
- Vol. 219 (2) , 392
Response to statin use and serum bilirubin levels
- Open Access
- 30 November 2011
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 10 (1) , 224
The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit
Background: High-density lipoproteins (HDL) and their main apolipoprotein, apoA-I, exhibit anti-inflammatory properties. The development of peptides that mimic HDL apolipoproteins offers a promising strategy to reduce inflammatory disease. This study aimed to compare the anti-inflammatory effects of ETC-642, an apoA-I mimetic peptide, with that of discoidal reconstituted HDL (rHDL), consisting of full-length apoA-I complexed with phosphatidylcholine, in rabbits with chronic vascular inflammation. Results: New Zealand White rabbits (n = 10/group) were placed on chow supplemented with 0.2% (w/w) cholesterol for 6-weeks. The animals received two infusions of saline, rHDL (8 mg/kg apoA-I) or ETC-642 (30 mg/kg peptide) on the third and fifth days of the final week. The infusions of rHDL and ETC-642 were able to significantly reduce cholesterol-induced expression of intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in the thoracic aorta (p < 0.05). When isolated rabbit HDL was pre-incubated with human coronary artery endothelial cells (HCAECs), prior to stimulation with TNF-α, it was found that HDL from ETC-642 treated rabbits were more effective at inhibiting the TNF-α-induced increase in ICAM-1, VCAM-1 and p65 than HDL isolated from saline treated rabbits (p < 0.05). There were, however, no changes in HDL lipid composition between treatment groups. Conclusions: Infusion of ETC-642 causes anti-inflammatory effects that are comparable to rHDL in an animal model of chronic vascular inflammation and highlights that apoA-I mimetic peptides present a viable strategy for the treatment of inflammatory disease.
- 30 November 2011
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 10 (1) , 224
Open AccessThe apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit
Background: High-density lipoproteins (HDL) and their main apolipoprotein, apoA-I, exhibit anti-inflammatory properties. The development of peptides that mimic HDL apolipoproteins offers a promising strategy to reduce inflammatory disease. This study aimed to compare the anti-inflammatory effects of ETC-642, an apoA-I mimetic peptide, with that of discoidal reconstituted HDL (rHDL), consisting of full-length apoA-I complexed with phosphatidylcholine, in rabbits with chronic vascular inflammation. Results: New Zealand White rabbits (n = 10/group) were placed on chow supplemented with 0.2% (w/w) cholesterol for 6-weeks. The animals received two infusions of saline, rHDL (8 mg/kg apoA-I) or ETC-642 (30 mg/kg peptide) on the third and fifth days of the final week. The infusions of rHDL and ETC-642 were able to significantly reduce cholesterol-induced expression of intracellular cell adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in the thoracic aorta (p < 0.05). When isolated rabbit HDL was pre-incubated with human coronary artery endothelial cells (HCAECs), prior to stimulation with TNF-α, it was found that HDL from ETC-642 treated rabbits were more effective at inhibiting the TNF-α-induced increase in ICAM-1, VCAM-1 and p65 than HDL isolated from saline treated rabbits (p < 0.05). There were, however, no changes in HDL lipid composition between treatment groups. Conclusions: Infusion of ETC-642 causes anti-inflammatory effects that are comparable to rHDL in an animal model of chronic vascular inflammation and highlights that apoA-I mimetic peptides present a viable strategy for the treatment of inflammatory disease.